<DOC>
	<DOCNO>NCT02427893</DOCNO>
	<brief_summary>This trial explore immunologic effect vemurafenib ( BRAF inhibitor ) cobimetinib ( MEK inhibitor ) , administer alone combination , patient advance BRAF V600E/K mutant melanoma .</brief_summary>
	<brief_title>Trial Vemurafenib Cobimetinib Patients With Advanced BRAFV600 Mutant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Signed informed consent Signed HIV test consent Life expectancy â‰¥ 12 week Able swallow pill ECOG performance status 2 less Adequate bone marrow function Adequate renal function Adequate liver function Negative urine pregnancy test within 7 day prior commencement dose premenopausal woman Histological diagnosis unresectable AJCC stage III stage IV , BRAFV600E/K mutant melanoma Measurable disease Accessible tumor biopsied Naive target therapy ( Prior immunebased therapy adjuvant set advanced disease allow &gt; 2 week study entry ) Active systemic infection Active autoimmune disease history know suspect autoimmune disease Active brain metastasis leptomeningeal metastasis Treatment immunomodulatory medication within 4 week initiation study therapy . Positive test hepatitis B virus Positive test hepatitis C virus Positive test human immunodeficiency virus ( HIV ) Pregnant , lactate breast feed woman Localized radiation therapy within last 14 day History malabsorption No consumption follow within 7 day prior start treatment : St. John 's wort hyperforin ( potent cytochrome P450 CYP3A4 enzyme inducer ) Grapefruit juice ( potent cytochrome P450 CYP3A4 enzyme inhibitor History evidence cardiovascular risk History evidence retinal pathology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>immunotherapy</keyword>
	<keyword>Vemurafenib</keyword>
	<keyword>Cobimetinib</keyword>
</DOC>